David Henke, MD MPH

Associate Professor of Medicine, Division of Pulmonary Diseases and Critical Care Medicine


Specialty Areas: Asthma

Chronology: BS:, University of Maryland, College Park, MD (1969); MPH: University of North Carolina, Chapel Hill, NC (1973) Public Health Honorary Delta Omega; MD: University of North Carolina at Chapel Hill, Chapel Hill, NC (1977) King Edward’s Fund Fellow (1974); Internal Medicine Residency: University of North Carolina at Chapel Hill (1980); Fellowship: Dermatology, University of North Carolina at Chapel Hill (1982), Pulmonary Medicine, University of North Carolina at Chapel Hill

Dr. Henke’s research interest as focused on providing care, developing innovative approaches to treating patients and developing ways to maintain health. My work in the laboratory has focused on understanding the role of host inflammatory responses in chronic diseases. This has led me to a novel approach for treating alveolar hemorrhage using Activated Factor VII (rFVIIa). My main focus has been to understand how the normal airway protects itself, with the goal of developing insight into the molecular basis for chronic inflammatory lung conditions, such as cystic fibrosis (CF), asthma, chronic obstructive pulmonary disease (COPD) and lung transplant graft failure.

Recent Bibliography:

Austin A, Henke DC, et al. Lower Respiratory Papillomatosis. New England Journal of Medicine, Submitted for publication, August 2015.

Pathak V, Kuhn J, Gabriel D, Barrow J, Jennette JC, Henke DC. Use of Activated Factor VII in Patients with Diffuse Alveolar Hemorrhage: A 10 years Institutional Experience. Lung 2015 Jun; 193(3) 375-9

Lux LJ, Posey RE, Daniels LS, Henke DC, Durham C, Jonas DE, Lohr KN. Pharmacokinetic/Pharmacodynamic Measures for Guiding Anitibiotic Treatment for Hospital-Acquired Pneumonia (Internet). Agency for Healthcare Research and Quality (US) Rockville (MD); 2014 Nov.

Pathak V, Kuhn JM, Durham C, Funkhouser WK, Henke DC. Marcolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. .Ann Am Thorac Soc. 2014 Jan; 11(1): 87-91.

Henke D, Crockett S, et al. Clinical Trial: High-Dose Acid Suppression for Chronic Cough: A Randomized, Double-Blind, Placebo-Controlled Trial. Alimentary Phamacology and Therapeutics. November 2010.

Henke DC, Jonas BL, Gabriel D. Activated Factor VII Therapy for Diffuse Alveolar Hemorrhage. US Respiratory Disease. Volume 5, Issue 2. pages 69-77. June 2010

Henke DC. Bench to Bedside for Curcuma longa L in Cystic Fibrosis-Curcumin’s Controversial Role as Therapy. US Respiratory Disease. Volume 4. Issue 2. pages 76-78. January 2009

Shaugnessy G, Henke DC. Case Report: Massive hemoptysis in a patient with a partially treated aspiration lung abscess. Infection in Medicine. Accepted 2007.

Olajide O, Henke DC, Gabriel DA. Hemorrhagic complications in bone marrow transplant: possible roles of recombinant activated coagulation factor VII, Transfusion Alternatives in Transfusion Medicine, Volume 8 issue s1, page 27-34; December 2006

Henke DC, Falk RJ, Gabriel DA. Successful Treatment of Diffuse Alveolar Hemorrhage in Different Clinical Settings Employing Activated Factor VIII, Annals of Internal Medicine – 2004, 140:493-494

Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasapheresis Therapy for Diffuse Alveolar Hemorrhage in Patients with Small Vessel Vasculitis, American Journal of Kidney Diseases, 42(6): 1149-1153, 2003